IL255448B2 - Inhibitors of histone deacetylase and their compositions and methods of use - Google Patents
Inhibitors of histone deacetylase and their compositions and methods of useInfo
- Publication number
- IL255448B2 IL255448B2 IL255448A IL25544817A IL255448B2 IL 255448 B2 IL255448 B2 IL 255448B2 IL 255448 A IL255448 A IL 255448A IL 25544817 A IL25544817 A IL 25544817A IL 255448 B2 IL255448 B2 IL 255448B2
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- mixture
- membered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158363P | 2015-05-07 | 2015-05-07 | |
| PCT/US2016/031335 WO2016179554A1 (en) | 2015-05-07 | 2016-05-06 | Histone deacetylase inhibitors and compositions and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL255448A0 IL255448A0 (en) | 2017-12-31 |
| IL255448B1 IL255448B1 (en) | 2023-03-01 |
| IL255448B2 true IL255448B2 (en) | 2023-07-01 |
Family
ID=57218014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255448A IL255448B2 (en) | 2015-05-07 | 2017-11-06 | Inhibitors of histone deacetylase and their compositions and methods of use |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10053434B2 (https=) |
| EP (1) | EP3291810B1 (https=) |
| JP (1) | JP6805172B2 (https=) |
| KR (1) | KR20180002729A (https=) |
| CN (1) | CN107735088B (https=) |
| AU (1) | AU2016258188B2 (https=) |
| CA (1) | CA2984618C (https=) |
| EA (1) | EA036965B1 (https=) |
| IL (1) | IL255448B2 (https=) |
| MX (1) | MX378983B (https=) |
| WO (1) | WO2016179554A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180002729A (ko) * | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
| EA035592B1 (ru) | 2015-05-07 | 2020-07-13 | Сиэйчдиай Фаундэйшн, Инк. | Ингибиторы деацетилаз гистонов и композиции и способы их применения |
| US10757941B2 (en) * | 2016-07-22 | 2020-09-01 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CN109627207A (zh) * | 2018-12-17 | 2019-04-16 | 天津药明康德新药开发有限公司 | 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法 |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| US20240327361A1 (en) * | 2021-02-15 | 2024-10-03 | The Research Foundation For The State University Of New York | Radiolabeled compositions and methods of use thereof |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013008162A1 (en) * | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1828171B1 (en) | 2004-12-10 | 2014-03-12 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
| CN103221047B (zh) | 2010-01-13 | 2014-12-17 | 坦颇罗制药股份有限公司 | 化合物和方法 |
| WO2013006408A1 (en) * | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009830A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| SI2750677T1 (sl) | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
| WO2013066835A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| CA2856334A1 (en) * | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| EP3130583B1 (en) * | 2012-04-05 | 2024-01-03 | CHDI Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| EA035592B1 (ru) | 2015-05-07 | 2020-07-13 | Сиэйчдиай Фаундэйшн, Инк. | Ингибиторы деацетилаз гистонов и композиции и способы их применения |
| KR20180002729A (ko) * | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
| ES2774510T3 (es) | 2015-07-27 | 2020-07-21 | Chong Kun Dang Pharmaceutical Corp | Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos |
| FI3328843T3 (fi) | 2015-07-27 | 2023-01-31 | 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus | |
| RU2709207C2 (ru) | 2015-08-04 | 2019-12-17 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их |
-
2016
- 2016-05-06 KR KR1020177034461A patent/KR20180002729A/ko not_active Withdrawn
- 2016-05-06 MX MX2017014300A patent/MX378983B/es unknown
- 2016-05-06 EA EA201792247A patent/EA036965B1/ru not_active IP Right Cessation
- 2016-05-06 CN CN201680040061.8A patent/CN107735088B/zh active Active
- 2016-05-06 AU AU2016258188A patent/AU2016258188B2/en active Active
- 2016-05-06 JP JP2017557324A patent/JP6805172B2/ja active Active
- 2016-05-06 US US15/148,907 patent/US10053434B2/en active Active
- 2016-05-06 CA CA2984618A patent/CA2984618C/en active Active
- 2016-05-06 EP EP16790203.0A patent/EP3291810B1/en active Active
- 2016-05-06 WO PCT/US2016/031335 patent/WO2016179554A1/en not_active Ceased
-
2017
- 2017-11-06 IL IL255448A patent/IL255448B2/en unknown
-
2018
- 2018-07-26 US US16/046,254 patent/US20190202795A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013008162A1 (en) * | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6805172B2 (ja) | 2020-12-23 |
| CA2984618C (en) | 2024-01-09 |
| AU2016258188A1 (en) | 2017-11-23 |
| US10053434B2 (en) | 2018-08-21 |
| JP2018515489A (ja) | 2018-06-14 |
| US20160326124A1 (en) | 2016-11-10 |
| IL255448B1 (en) | 2023-03-01 |
| MX378983B (es) | 2025-03-10 |
| CN107735088B (zh) | 2021-11-02 |
| AU2016258188B2 (en) | 2021-08-26 |
| EA201792247A1 (ru) | 2018-06-29 |
| EP3291810B1 (en) | 2022-08-10 |
| EP3291810A1 (en) | 2018-03-14 |
| WO2016179554A1 (en) | 2016-11-10 |
| EA036965B1 (ru) | 2021-01-20 |
| US20190202795A1 (en) | 2019-07-04 |
| CN107735088A (zh) | 2018-02-23 |
| MX2017014300A (es) | 2018-08-09 |
| EP3291810A4 (en) | 2018-11-07 |
| IL255448A0 (en) | 2017-12-31 |
| BR112017023711A2 (pt) | 2018-07-17 |
| CA2984618A1 (en) | 2016-11-10 |
| HK1252487A1 (en) | 2019-05-24 |
| KR20180002729A (ko) | 2018-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016256917B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| EP3291810B1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| US9765054B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| US9783488B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| EP2871955A1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| EP2968207A1 (en) | Histone deacetylase inhibitors and compositions | |
| HK1252487B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| HK1252489B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| BR112017023711B1 (pt) | Inibidores de histona deacetilase e composições e métodos de uso dos mesmos |